Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

StackMD vs TeleFirst Med

StackMD
Graded #259

Higher grade

vs+6
TeleFirst Med
Graded #400

Lower grade

The verdict

StackMD takes it — 63.4/100 to 57.4/100.

StackMD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. StackMD is a New York telehealth platform (Medical 360 HC PLLC) selling compounded semaglutide and tirzepatide, both formulated with B12 and glycine, alongside NAD+, sermorelin and other longevity peptides.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueStackMD +1
46
45
Dose & formulationStackMD +1
54
53
Clinical oversightTeleFirst Med +4
78
82
Labs & monitoringStackMD +10
62
52
FulfillmentStackMD +31
89
58
Contract termsStackMD +14
69
55
StackMD · left barTeleFirst Med · right bar

The numbers

MetricStackMDTeleFirst Med
WeighScore63.4/10057.4/100
GradeCC
Scorecard rank#259#400
Semaglutide$125/mo (1 mg dose, plus a separate fee, compounded)Not disclosed
Tirzepatide$199/mo (5 mg dose, compounded)Not disclosed
CoverageAll 50 states2 states
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyInjection only
StackMD

Graded #259 · C

Strengths

  • Publishes an exact price for every dose strength rather than a single 'from' figure — semaglutide $125-$225, tirzepatide $199-$449
  • Names both its legal entity (Medical 360 HC PLLC) and its prescribing telehealth partner, SamaritanMD
  • No membership or platform fee — the medication price is the whole price
  • States plainly that its compounded medications are 'not FDA-approved and have not been evaluated by the FDA for safety, efficacy, or quality'
  • Telehealth offered in all 50 states per its terms, with free discreet shipping and FSA/HSA eligibility

Where it loses points

  • All sales are final — 'No refunds are issued except as described below', and dispensed medication cannot be returned
  • Compounding pharmacies are never named, only 'a licensed third-party pharmacy'
  • Price rises steeply with dose: tirzepatide runs $199 at 5mg to $449 at 30mg
  • Billing and refunds are handled by SamaritanMD — StackMD 'has no authority to issue refunds' on its behalf
  • Terms impose binding arbitration in New York and waive jury trial and class-action participation
TeleFirst Med

Graded #400 · C

Strengths

  • Prescribes real brand-name GLP-1 (e.g. Ozempic/Wegovy), not compounded — appealing if you specifically want FDA-approved branded medication
  • Simple $120 telehealth evaluation with a licensed doctor; no insurance hassle and no prior authorization
  • You fill the prescription at your own regular pharmacy rather than waiting on a mail-order compounding pharmacy
  • Also a general telehealth clinic (urgent care, chronic-condition management) if you want broader care

Where it loses points

  • Only Texas and North Carolina are confirmed — not available nationwide
  • The $120 is an evaluation fee; the brand-name medication is billed separately at your pharmacy and can be expensive without insurance
  • Small practice (about 500 patients) with limited public detail on its clinicians and program
  • No compounded or lower-cost medication option, and no medication pricing is published

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard